Fangzhou Inc. reported strong financial results for the first half of 2025, with revenue increasing by 12.9% to RMB 1.494 billion compared to the same period last year. The company achieved a net profit of RMB 12.5 million, a significant improvement from a net loss of RMB 818.7 million in the previous year. Adjusted net profit also grew by 16.8% to RMB 17.6 million, setting a new record for the company. The growth in revenue and profitability was supported by an expanding user base and increased operational efficiency, driven by the accelerated deployment of AI across various services. Fangzhou's registered users grew by 15.8% to 52.8 million, while monthly active users increased by 34.4% to 11.9 million. The number of registered doctors on the platform rose to 229,000, and the paid user repurchase rate increased to 85.4%. The company's online retail pharmacy services saw revenue climb by 28.2% to RMB 864 million, and medical services revenue rose by 11.4% to RMB 357 million. Fangzhou has also expanded its drug catalog to 215,000 SKUs, with prescription medicines making up approximately 62% of this inventory. The company has built robust supply chain partnerships with over 1,650 suppliers and more than 980 pharmaceutical firms, and it launched several innovative drugs from major pharmaceutical companies during the period. Fangzhou continues to enhance its integration with China's national medical insurance system, improving service capabilities and laying the groundwork for broader regional expansion. The company remains focused on delivering sustained growth and contributing to the "Healthy China 2030" goals through its strategic initiatives and partnerships.